[2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients].

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bulletin du Cancer

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1684/bdc.2008.0678PMID 18755652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thromboprophylaxis for catheter‐related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials

  2007cited by this paper
• Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters.

  2007cited by this paper
• Prevention of catheter‐related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo‐controlled study

  2007cited by this paper
• The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis.

  2007cited by this paper
• Thromboprophylaxis in cancer patients with central venous catheters

  2007cited by this paper
• Prevention of central venous catheter-associated thrombosis: a meta-analysis.

  2007cited by this paper
• Inferior Vena Cava Filter Placement in Late-Stage Cancer

  2006influential reference
• Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

  2006cited by this paper
• High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens.

  2006cited by this paper
• Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.

  2006cited by this paper
• Low‐dose warfarin for the prevention of central line‐associated thromboses in children with malignancies—a randomized, controlled study

  2006cited by this paper
• Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies.

  2006cited by this paper
• Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study

  2006cited by this paper
• Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

  2006cited by this paper
• Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence

  2006cited by this paper
• Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.

  2006cited by this paper
• Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.

  2006cited by this paper
• Vena cava filters in cancer patients: experience with 50 patients.

  2005cited by this paper
• Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.

  2005cited by this paper
• WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs)

  2005cited by this paper
• Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports

  2005cited by this paper
• [Symptomatic thrombosis in central venous catheter in oncology: a predictive score?].

  2005cited by this paper
• Thrombose symptomatique sur cathéter veineux central de longue durée en oncologie : un score de risque prédictif?

  2005cited by this paper
• Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.

  2005cited by this paper
• Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.

  2005cited by this paper
• Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study

  2005cited by this paper
• Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

  2005cited by this paper
• Thrombotic complications of implanted central venous access devices: prospective evaluation.

  2004cited by this paper
• To clot or not to clot? That is the question in central venous catheters.

  2004cited by this paper
• Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease

  2004cited by this paper
• Use of inferior vena caval filters and survival in patients with malignancy

  2004cited by this paper
• Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism

  2004cited by this paper
• A prospective randomized trial demonstrating valved implantable ports have fewer complications and lower overall cost than nonvalved implantable ports.

  2004cited by this paper
• Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

  2003cited by this paper
• Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?

  2003cited by this paper
• Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review.

  2003cited by this paper
• Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen.

  2003cited by this paper
• Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants

  2003cited by this paper
• Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.

  2003cited by this paper
• Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

  2002cited by this paper
• Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US.

  2002cited by this paper
• Inferior vena cava filters in malignant disease.

  2002influential reference
• Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis

  2002cited by this paper
• Low molecular weight heparin for deep vein thrombosis in glioma patients

  2002cited by this paper
• PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS

  2002cited by this paper
• Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.

  2002cited by this paper
• Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study.

  2002cited by this paper
• Catheter-related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Prospective Study Based on Doppler US

  2001cited by this paper
• A randomized, prospective trial of central venous ports connected to standard open‐ended or Groshong catheters in adult oncology patients

  2001cited by this paper
• SOR: project methodology

  2001cited by this paper
• Thromboembolism in brain tumors

  2001cited by this paper
• A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.

  2000cited by this paper
• Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis.

  2000cited by this paper
• Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis.

  2000cited by this paper
• A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy

  2000cited by this paper
• The Treatment and Outcome of Cancer Patients with Thromboses on Central Venous Catheters

  2000cited by this paper
• Outpatient Use of Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity

  1999cited by this paper
• Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.

  1999cited by this paper
• Regional Thrombolysis with Urokinase for Central Venous Catheter-related Thrombosis in Patients Undergoing High-dose Chemotherapy with Autologous Blood Stem Cell Rescue

  1999cited by this paper
• Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis

  1999cited by this paper
• Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism.

  1998cited by this paper
• Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?

  1998cited by this paper
• A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy.

  1997cited by this paper
• Clinical Results of Greenfield Filter Use in Patients with Cancer

  1997cited by this paper
• Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.

  1997cited by this paper
• Inferior vena cava filters in cancer patients: indications and outcome.

  1996cited by this paper
• [Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis].

  1996cited by this paper
• Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.

  1996cited by this paper
• [Classical anticoagulant treatment of venous thromboembolic disease in cancer patients. Apropos of a retrospective study of 71 patients].

  1996cited by this paper
• Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)

  1996cited by this paper
• Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications.

  1996cited by this paper
• Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. A propos d'une série rétrospective de 71 patients

  1996cited by this paper
• Fibrinolyse des thromboses veineuses profondes sur dispositifs de perfusion implantables. A propos d'une série consécutive de 57 thromboses et de 32 fibrinolyses.

  1996cited by this paper
• Complications of indwelling venous access devices in cancer patients.

  1995cited by this paper
• Methodologie de developpement des standards, options et recommandations diagnostiques et therapeutiques en cancerologie

  1995cited by this paper
• Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.

  1995cited by this paper
• [Methodology of the development of diagnostic and therapeutic standards, options and recommendations in oncology].

  1995cited by this paper
• Therapy of venous thromboembolism in patients with brain metastases

  1994cited by this paper
• Thromboembolism in patients with high-grade glioma.

  1994cited by this paper
• The Bird's Nest Filter: An Alternative to Long‐Term Oral Anticoagulation in Patients with Advanced Malignancies

  1994cited by this paper
• Venous Thromboembolism and High Grade Gliomas

  1993cited by this paper
• Complications of therapy for venous thromboembolic disease in patients with brain tumors

  1993cited by this paper
• Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.

  1993cited by this paper
• Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy.

  1992cited by this paper
• Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer

  1992cited by this paper
• The Incidence and significance of thromboembolic complications in patients with high‐grade gliomas

  1991cited by this paper
• Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer.

  1991cited by this paper
• Thromboembolic complications in patients with advanced cancer: Anticoagulation versus greenfield filter placement

  1991cited by this paper
• The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors.

  1990cited by this paper
• Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.

  1990cited by this paper
• Incidence and treatment of peripheral venous thrombosis in patients with glioma

  1983cited by this paper
• Incidence of lower extremity deep vein thrombosis in neurosurgical patients.

  1980cited by this paper

• Management of venous thromboembolism in cancer patients according to guidelines after educative measures.

  2018cites this paper
• [Thrombosis and cancer: Awareness of private practitioners and patients in Poitou-Charentes, a French region].

  2018cites this paper
• Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review.

  2016cites this paper
• [Prevalence, indication and compliance with the recommendations of prescription of low molecular weight heparin in oncology].

  2015cites this paper
• Prévalence, indication et conformité aux recommandations de prescription d’héparine de bas poids moléculaire en oncologie

  2015cites this paper
• The Cost of Thromboembolic Events in Hospitalized Patients with Breast or Prostate Cancer in France

  2015cites this paper
• New strategies of VTE prevention in cancer patients.

  2014cites this paper
• Pose de chambre implantable par abord percutané échoguidé : à propos d’une série de 102 patients

  2013cites this paper
• [Ultrasound-guided percutaneous insertion of implantable venous devices: a review of 102 patients].

  2013cites this paper
• Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.

  2013cites this paper
• New and old anticoagulants in cancer.

  2012cites this paper
• Management of venous thromboembolism in patients with cancer

  2011cites this paper
• Cancer-associated thrombosis.

  2010cites this paper
• Enquête étiologique au cours de la maladie veineuse thromboembolique

  2010cites this paper
• Cancer-related venous thromboembolism: insight into underestimated risk factors.

  2010cites this paper
• Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines.

  2010cites this paper
• Cancer, clots and consensus: new understanding of an old problem.

  2009cites this paper